BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200722
DTEND;VALUE=DATE:20200723
DTSTAMP:20260515T101241
CREATED:20200302T091243Z
LAST-MODIFIED:20200514T082403Z
UID:24438-1595376000-1595462399@www.pharmajournalist.com
SUMMARY:Innate Immune Stimulating Therapies Summit – Running Digitally for 2020
DESCRIPTION:Safely Harnessing Novel Targets of the Innate Immune System for Enhanced Anti-Tumor Effects \nThe inaugural Innate Immune Stimulating Therapies Summit is focused on achieving safe and effective clinical and commercial translation of STING and TLR therapies. \n \nJoin the leaders in the field\, from key biotech\, large pharma\, and academia\, to discuss how to optimize the administration of innate immune stimulating therapies from IT delivery through to antibody conjugated approaches. \nIf you are looking to make long lasting connections with industry leaders and take part in discussions about the lessons learned on the journey to translating safe and effective innate immune stimulating therapies for patients in need\, then this is the meeting for you. Join our online community of industry experts here: https://ter.li/52s56v. Earlybird and group discounts apply. Book early to secure the best possible rate on your ticket.
URL:https://www.pharmajournalist.com/event/innate-immune-stimulating-therapies-summit/
LOCATION:Online\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200722
DTEND;VALUE=DATE:20200723
DTSTAMP:20260515T101241
CREATED:20200612T152417Z
LAST-MODIFIED:20200612T155249Z
UID:25917-1595376000-1595462399@www.pharmajournalist.com
SUMMARY:RNAi-Based Therapeutics Summit – Running Digitally for 2020
DESCRIPTION:Digitally Join the RNAi-Based Therapeutics Community \nWe are excited to announce that the RNAi-Based Therapeutics Summit has gone virtual! \nAs the first multi-disciplinary discussion for large pharma\, biotech and academic leaders specifically dedicated to the RNAi therapeutics\, the industry will be coming together on Wednesday\, July 22 to successfully optimize cell-specific strategies\, overcome pharmacology and delivery challenges to accelerate translation and clinical development of RNAi therapeutics in the liver\, CNS and beyond. \nCheck out the official event guide for full speaker and session details. \nJoin this virtual summit to meet those pioneering the field and to hear from 19+ world-class experts that are sharing their latest perspectives: \n\nDong-ki Lee\, Founder & Chief Executive Officer\, OliX Pharmaceuticals\nElena Feinstein\, Chief Scientific Officer\, Quark Pharmaceuticals\nKaryn O’Neil\, Chief Scientific Officer\, Aro Biotherapeutics\nBrooke Rock\, Director\, Amgen\nSharmistha Ghosh\, Associate Director\, Arrowhead Pharmaceuticals\nBaisong Mei\, Senior Global Project Head\, Sanofi\nDavid Corey\, Professor\, UT Southwestern\n\nDownload the updated program to see the full list. \nWith several clinical candidates emerging and momentum building in the field\, join the RNAi-Based Therapeutics Summit – your comprehensive\, industry-focused virtual meeting dedicated to bringing together senior biopharmaceutical leaders from discovery\, translation\, and clinical development functions to advance pioneering RNAi platforms that improve patient outcomes. Secure your ticket now. \nLooking forward to seeing you at our virtual meeting!
URL:https://www.pharmajournalist.com/event/rnai-based-therapeutics-summit-running-digitally-for-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR